We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+9.85%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.6B
AUM Growth
+$151M
Cap. Flow
-$15.9M
Cap. Flow %
-0.61%
Top 10 Hldgs %
41.87%
Holding
167
New
13
Increased
21
Reduced
24
Closed
25

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$27.5M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$23.6M
3
VTRS icon
Viatris
VTRS
+$18.4M
4
ABT icon
Abbott
ABT
+$18.2M
5
CVS icon
CVS Health
CVS
+$17.7M

Top Sells

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$20.5M
2
HCA icon
HCA Healthcare
HCA
+$18.3M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$15.9M
4
MDVN
MEDIVATION, INC.
MDVN
+$15.5M
5
STJ
St Jude Medical
STJ
+$12.4M

Sector Composition

Rank Sector Weight
1 Healthcare 91.79%
2 Real Estate 2.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVNC
126
DELISTED
Revance Therapeutics, Inc.
RVNC
$1.22M 0.05%
75,000
– –
BLCM
127
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$1.19M 0.05%
6,000
– –
NVAX icon
128
Novavax
NVAX
$1.22B
$1.19M 0.05%
28,550
+10,650
+59% +$1.37M
GNMK
129
DELISTED
GenMark Diagnostics, Inc
GNMK
$1.1M 0.04%
93,349
– –
AFMD
130
DELISTED
Affimed
AFMD
$818K 0.03%
29,421
– –
TTPH
131
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$737K 0.03%
9,616
– –
XNCR icon
132
Xencor
XNCR
$1.59B
$490K 0.02%
20,000
– –
QHC
133
DELISTED
Quorum Health Corporation
QHC
$477K 0.02%
76,118
– –
CLDX icon
134
Celldex Therapeutics
CLDX
$3.02B
$427K 0.02%
7,053
– –
RMR icon
135
The RMR Group
RMR
$333M
$282K 0.01%
7,441
– –
LRMR icon
136
Larimar Therapeutics
LRMR
$398M
$44K ﹤0.01%
1,109
– –
ABBV icon
137
AbbVie
ABBV
$455B
$10K ﹤0.01%
156
– –
ABT icon
138
CALL
Abbott
ABT
$183B
– –
-123,800
Closed -$4.87M
ALKS icon
139
CALL
Alkermes
ALKS
$8.39B
– –
-111,900
Closed -$4.84M
AMGN icon
140
CALL
Amgen
AMGN
$209B
– –
-10,100
Closed -$1.54M
AZN icon
141
CALL
AstraZeneca
AZN
$266B
– –
-55,100
Closed -$3.33M
BMRN icon
142
CALL
BioMarin Pharmaceuticals
BMRN
$11.7B
– –
-57,700
Closed -$4.49M
COR icon
143
CALL
Cencora
COR
$60.7B
– –
-41,500
Closed -$3.29M
GILD icon
144
CALL
Gilead Sciences
GILD
$163B
– –
-57,400
Closed -$4.79M
GSK icon
145
CALL
GSK
GSK
$104B
– –
-60,160
Closed -$3.26M
HRTX icon
146
Heron Therapeutics
HRTX
$94.1M
– –
-492,303
Closed -$8.89M
NBIX icon
147
CALL
Neurocrine Biosciences
NBIX
$18.7B
– –
-110,400
Closed -$5.02M
VTRS icon
148
CALL
Viatris
VTRS
$20.7B
– –
-104,600
Closed -$4.52M
XBI icon
149
State Street SPDR S&P Biotech ETF
XBI
$10.3B
– –
-294,000
Closed -$15.9M
ITCI
150
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-187,800
Closed -$7.29M
3 4 5
6
7

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2016 Portfolio in Review

As of Q3 2016, Tekla Capital Management held 167 positions worth $2.6B, up 6.1% from $2.45B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Tekla Capital Management's Q3 2016 filing shows 13 new, 21 increased, 24 reduced and 25 closed positions. Its largest new stake was Cardinal Health: 152,500 shares worth $11.8M. The largest sale was Illumina, an estimated $20.5M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 86% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q3 2016 buy was Cardinal Health: 152,500 shares worth $11.8M.
  • Tekla Capital Management added most to Merck in Q3 2016, an estimated $27.5M increase.
  • Tekla Capital Management's biggest Q3 2016 reduction was Illumina, cutting an estimated $20.5M.
  • Tekla Capital Management fully exited State Street SPDR S&P Biotech ETF in Q3 2016, selling an estimated $15.9M.
  • Tekla Capital Management's ten largest holdings make up 42% of its $2.6B portfolio in Q3 2016.
  • Tekla Capital Management opened 13 new positions and closed 25 in Q3 2016.
  • Tekla Capital Management's portfolio value rose 6.1% quarter-over-quarter to $2.6B.

Based on Tekla Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.